Switching to a new entecavir form for liver transplant patients
Part of Digestive system, Infections clinical trials.
This trial tests whether switching from the regular entecavir pill to a new orally dissolving version works just as well and is safe for patients who have had a liver transplant due to hepatitis B. If you've been stable on entecavir, this could be a convenient alternative.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older
- You have had a stable liver transplant for at least one year due to hepatitis B, with normal liver tests and no detectable hepatitis B virus in your blood
- You have been taking the antiviral drug entecavir for at least one year
- Your tacrolimus (anti-rejection medicine) level is in a specific range (3–10 ng/mL)
- You have not had a transplant of another organ or a re-transplant
- You do not have other viral infections like hepatitis C or HIV, and your kidney function is adequate (not on dialysis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether switching to a newer antiviral medicine called tenofovir alafenamide (TAF, a pill for hepatitis B) is safe and works well for people who have had a liver transplant. The goal is to keep the liver healthy and reduce side effects compared to current treatment.
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
This study tests two daily doses of the medicine entecavir to see which one better controls the hepatitis B virus in people with advanced liver scarring (cirrhosis). It aims to find the most effective dose to improve liver health.
This trial tests whether giving the antiviral drug entecavir before or at the first sign of hepatitis B reactivation can prevent liver problems in gastrointestinal cancer patients who are inactive hepatitis B carriers and are starting chemotherapy or immunotherapy.
This study compares two treatments for children aged 3 to 6 with chronic hepatitis B. One group gets the standard medicine entecavir, and the other gets entecavir plus a medicine that helps the immune system fight the virus (peginterferon). The goal is to see if the combination works better.
This study tests whether adding a second medicine to the standard hepatitis B treatment helps young children clear the virus better. It may help improve liver health and reduce long-term risks.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.